Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
- 7 September 2018
- journal article
- research article
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 35 (10), 992-1000
- https://doi.org/10.1002/da.22832
Abstract
Background Definition of response is critical when seeking to establish valid predictors of treatment success. However, response at the end of study or endpoint only provides one view of the overall clinical picture that is relevant in testing for predictors. The current study employed a classification technique designed to group subjects based on their rate of change over time, while simultaneously addressing the issue of controlling for baseline severity. Methods A set of latent class trajectory analyses, incorporating baseline level of symptoms, were performed on a sample of 344 depressed patients from a clinical trial evaluating the efficacy of cognitive behavior therapy and two antidepressant medications (escitalopram and duloxetine) in patients with major depressive disorder. Results Although very few demographic and illness‐related features were associated with response rate profiles, the aggregated effect of candidate genetic variants previously identified in large pharmacogenetic studies and meta‐analyses showed a significant association with early remission as well as nonresponse. These same genetic scores showed a less compelling relationship with endpoint response categories. In addition, consistent nonresponse throughout the study treatment period was shown to occur in different subjects than endpoint nonresponse, which was verified by follow‐up augmentation treatment outcomes. Conclusions When defining groups based on the rate of change, controlling for baseline depression severity may help to identify the clinically relevant distinctions of early response on one end and consistent nonresponse on the other.Keywords
Funding Information
- National Institute of Mental Health (K23 MH086690, P50 MH077083, R01 MH080880)
This publication has 56 references indexed in Scilit:
- No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysisAnnals of General Psychiatry, 2013
- Benefits From AntidepressantsArchives of General Psychiatry, 2012
- Trajectories of Depression Severity in Clinical Trials of DuloxetineArchives of General Psychiatry, 2011
- GCTA: A Tool for Genome-wide Complex Trait AnalysisAmerican Journal of Human Genetics, 2011
- Growth modeling with nonignorable dropout: Alternative analyses of the STAR*D antidepressant trial.Psychological Methods, 2011
- How Placebos Change the Patient's BrainNeuropsychopharmacology, 2010
- Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorderJournal of Psychiatric Research, 2010
- SLC6A4 variation and citalopram responseNeuropsychiatric Genetics, Part B of the American Journal of Medical Genetics (AJMG), 2008
- The FKBP5-Gene in Depression and Treatment Response—an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) CohortBiological Psychiatry, 2008
- Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant TreatmentAmerican Journal of Human Genetics, 2006